Evoke Pharma will conduct at-the-market sale of 649,074 common shares

FBR Capital Markets assists; deal to finance development requirements

By Devika Patel

Knoxville, Tenn., April 15 – Evoke Pharma, Inc. negotiated an at-the-market equity offering of up to 649,074 common shares with agent FBR Capital Markets & Co. on April 15, according to an 8-K and prospectus supplement filed Friday with the Securities and Exchange Commission.

The agent will be paid a 3% commission.

Proceeds will be used for any additional development requirements requested by the FDA, as well as for New Drug Application preparation and pre-commercial activities, including marketing and manufacturing of EVK-001, and for working capital and general corporate purposes.

The specialty pharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.